In 2021 Susan is focusing on Access and Benefit Sharing (ABS), opportunities for strategic partnering, and commercialization of microbiome peptides as COVID-19 therapeutics, including non-science regulatory issues, corporate identity, intellectual property (IP) management, R&D collaboration, vendor selection, and related commercialization issues.

Past assignments include:

• Successful licensing transaction as part of the historic divestment of assets by largest Canadian pharmaceutical company to a MENA-based pharmaceutical company (2019)
• Conceptualization, seed funding and management for oncology microbiome company
  Amrita Therapeutics Limited (India) (2009 – 2018)
• Conceptualization and management of the Washington Embassy Network (WEN) (2006 – 2015), organizing luncheon briefings on trade, intellectual property and investment issues for senior diplomats in Washington DC (2006 – 2015)
• Co-founder and Executive Director, American BioIndustry Alliance (ABIA) providing strategic advocacy for biotechnology companies in support of the historic Convention on Biological Diversity (CBD) Nagoya Protocol on Access and Benefit Sharing (ABS) for genetic resources (GR) and associated Traditional Knowledge (TK) (2005 – 2009)
• Advice on strategic partnering, with benchmarks including successful matchmaking between a leading South Asian and a Fortune-100 biopharma company (2008)
• Industry negotiator for World Trade Organization (WTO) Accession agreements for Saudi Arabia, Gulf Cooperation Council (GCC) and Jordan, as Associate Vice President, Pharmaceutical Research and Manufacturers of America (PhRMA), where she also led multinational industry campaign for reintroduction of product patent protection in India (1999 – 2005)